Lifecore Biomedical said Monday it has entered into a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to $663.7 million, assuming full achievement of certain performance milestones. Under the terms, an entity affiliated with Webster Equity Partners will acquire all outstanding Lifecore common stock for $6.28 per share in cash at closing plus one non-tradable contingent value right per share. The initial cash consideration of $6.28 per share represents a premium of about 49.5% to Lifecore's closing price on September 25, 2026, the last full trading day before signing the merger agreement. Assuming full CVR performance milestone payments of $160 million, the aggregate potential merger consideration of $9.67 per share represents a premium of approximately 130.2% to that same closing price. Upon completion, Lifecore's common stock will be delisted from the Nasdaq Stock Market, and the merger agreement includes a 30-day go-shop period during which Lifecore and its advisors may solicit and negotiate alternative acquisition proposals. The transaction is expected to close at the end of the fourth quarter of 2026.
Lifecore Biomedical Inc.Lifecore agrees to be acquired by Webster Equity Partners for $6.28/share cash plus CVRs, a ~49.5% premium, and will be delisted.
Webster Equity Partners is the acquirer in the up-to-$663.7 million take-private deal for Lifecore Biomedical.
